Ligand Pharmaceuticals (LGND) Chief Legal Officer and Secretary Andrew Reardon exercised 340 employee stock options on October 2, 2026, at a $52.27 exercise price, acquiring 340 common shares; 29,104 options remained after the exercise. That day, he sold 5,000 common shares in six transactions under a written Rule 10b5-1 plan adopted June 4, 2026. Five sale blocks carried weighted-average prices of $302.5107 (833 shares), $303.5444 (1,976 shares), $304.5154 (1,535 shares), $306.1834 (404 shares), and $307.1911 (235 shares); another 17 shares were reported at $307.7400.
Ligand Pharmaceuticals Inc. director Martine Zimmermann had 115 shares withheld by the issuer on September 22, 2026, to pay tax liability arising from restricted stock unit settlement. The reported price was $298.50 per share, and Zimmermann’s direct holdings after the transaction were 3,782 shares. No Rule 10b5-1 plan is reported.
Ligand Pharmaceuticals Incorporated (LGND) reported that it has acquired royalty and milestone payment rights related to Santen Pharmaceutical’s Ryjunea® from Sydnexis, Inc. for a $23 million upfront payment. The rights are tied to an existing license agreement between Sydnexis and Santen covering Europe, the Middle East and Africa.
Ligand will receive an ascending, tiered low-double-digit to high-teens royalty on Ryjunea net sales in EMEA, plus specified milestone payments, while Sydnexis retains commercial rights in the U.S. and other non-Santen territories. Ryjunea is a once-nightly 0.01% low-dose atropine eye drop approved by the European Commission in June 2025 and by the UK MHRA in October 2025 to slow progression of pediatric myopia. Ligand describes this as a differentiated addition to its royalty portfolio, noting Santen’s strategic focus on myopia and estimating a large addressable market, with Santen citing 14 million myopia patients in Europe in 2025.
LIGAND PHARMACEUTICALS INC (LGND) director Martine Zimmermann reported selling 1,200 shares of common stock on September 10, 2026 in an open market or private transaction at $285.00 per share. After this sale, Zimmermann directly holds 3,897 shares of LGND common stock, and no Rule 10b5-1 trading plan is reported.
LIGAND PHARMACEUTICALS INC (LGND) has a notice of proposed sale of common stock filed on behalf of director Martine Zimmermann under Rule 144. The notice covers 1,200 shares of common stock, with an aggregate market value of $342,000, to be sold through Morgan Stanley Smith Barney LLC on or about September 10, 2026 on NASDAQ.
The shares to be sold relate to restricted stock issued by the company, including 438 shares from a grant dated June 6, 2025 and 762 shares from a grant dated September 22, 2024. Shares outstanding are stated as 19,935,609, a baseline figure, not the amount being sold.
LIGAND PHARMACEUTICALS INC (LGND) reported that its Chief Legal Officer and Secretary, Andrew Reardon, sold a total of 5,000 shares of common stock on September 3, 2026. The sales were made in multiple open-market transactions at weighted-average prices between about $283.43 and $289.43, pursuant to a written Rule 10b5-1 trading plan adopted on June 4, 2026.
Ligand Pharmaceuticals Incorporated (LGND) filed an amended current report to add historical financial statements for its recently acquired subsidiary XOMA Royalty Corporation and unaudited pro forma combined financial information reflecting the completed merger. XOMA Royalty operates as a royalty aggregator with a large portfolio of milestone, royalty, and commercial payment rights.
As of June 30, 2026, XOMA Royalty reported total assets of $244.3 million, including cash, cash equivalents and restricted cash of $150.6 million, and total liabilities of $157.1 million, leaving stockholders’ equity of $87.3 million. Long-term and current debt together totaled about $103.1 million. For the six months ended June 30, 2026, XOMA generated $29.3 million of income and revenues but recorded a net loss of $41.2 million, driven by $23.6 million of impairment charges and $19.7 million of credit losses on purchased receivables.
Royalty and commercial payment receivables were significant, with $30.0 million accounted for under the Effective Interest Rate method and $36.2 million under the cost recovery method. Despite the loss, XOMA reported $4.6 million of net cash provided by operating activities in the first half of 2026 and concluded its liquidity is sufficient to fund planned operations, commitments, and obligations for at least one year after the financial statements’ issuance date.
LIGAND PHARMACEUTICALS INC’s Chief Financial Officer, Octavio Espinoza, reported option-related transactions and a share sale on August 12, 2026. He exercised stock options covering 31,641 shares of common stock at exercise prices between $52.84 and $70.04 per share, then sold 31,641 shares of common stock at a weighted-average price of $292.065 per share in multiple transactions. The company notes these trades were made under a written Rule 10b5-1 trading plan adopted on May 13, 2026.
Ligand Pharmaceuticals director Jason Haas reported an option exercise and share sale dated August 12, 2026. He exercised a Non-Qualified Stock Option for 6,138 shares of common stock at an exercise price of $51.56 per share, fully disposing of this option grant. He then reported acquiring 6,138 common shares from the exercise and selling 7,138 common shares at a weighted-average price of $292.8078 per share, with individual sale prices ranging from $292.5000 to $292.8550. The Rule 10b5-1 trading-plan checkbox was not marked for these transactions.
Invesco Ltd. reports a significant ownership stake in Ligand Pharmaceuticals Inc. common stock. Invesco, as a parent holding company to its investment advisers, may be deemed to beneficially own 1,218,846 shares of Ligand, representing 6.1% of the outstanding common stock as of June 30, 2026.
Invesco has sole voting power over 1,199,033 shares and sole dispositive power over 1,218,846 shares, with no shared voting or dispositive power. The shares are held of record by Invesco’s advisory clients, who have the right to receive dividends and sale proceeds, and no single client has more than 5% economic ownership of the class.